LIFEVANTAGE CORP Operating Lease, Right-of-Use Asset, Amortization Expense
LIFEVANTAGE CORP (LFVN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.39 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-27
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $350.00K, a 5.91% decline year-over-year.
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $348.00K, a 3.06% decline year-over-year.
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $346.00K, a 2.81% decline year-over-year.
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $345.00K, a 2.27% decline year-over-year.
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for fiscal 2026 was $1.39M, a 3.54% decline from fiscal 2025.
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.44M, a 11.89% increase from fiscal 2024.
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.29M, a 26.37% decline from fiscal 2023.
- LIFEVANTAGE CORP operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.75M, a 2.13% decline from fiscal 2022.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $698.00K derived: sum of 2 quarters · filed 2026-08-27 | $1.04M derived: sum of 3 quarters · filed 2026-08-27 | $1.39M 10-K · filed 2026-08-27 |
| 2026-03-31 | $348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $694.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.04M 10-Q · filed 2026-05-06 | $1.41M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-12-31 | $346.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $691.00K 10-Q · filed 2026-02-04 | $1.06M derived: sum of 3 quarters · filed 2026-08-27 | $1.42M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-09-30 | $345.00K 10-Q · filed 2025-11-04 | $717.00K derived: sum of 2 quarters · filed 2026-08-27 | $1.08M derived: sum of 3 quarters · filed 2026-08-27 | $1.43M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-06-30 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $731.00K derived: sum of 2 quarters · filed 2026-08-27 | $1.09M derived: sum of 3 quarters · filed 2026-08-27 | $1.44M 10-K · filed 2026-08-27 |
| 2025-03-31 | $359.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $715.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.07M 10-Q · filed 2026-05-06 | $1.44M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $356.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $709.00K 10-Q · filed 2026-02-04 | $1.08M derived: sum of 3 quarters · filed 2026-02-04 | $1.42M derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-09-30 | $353.00K 10-Q · filed 2025-11-04 | $720.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.06M derived: sum of 3 quarters · filed 2025-11-04 | $1.42M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-04 | $712.00K derived: sum of 2 quarters · filed 2025-09-04 | $1.07M derived: sum of 3 quarters · filed 2025-09-04 | $1.29M 10-K · filed 2025-09-04 |
| 2024-03-31 | $345.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-06 | $704.00K derived: sum of 2 quarters · filed 2025-05-06 | $920.00K 10-Q · filed 2025-05-06 | $1.41M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $359.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-05 | $575.00K 10-Q · filed 2025-02-05 | $1.07M derived: sum of 3 quarters · filed 2025-02-05 | $1.56M derived: sum of 4 quarters · filed 2025-02-05 |
| 2023-09-30 | $216.00K 10-Q · filed 2024-10-29 | $707.00K derived: sum of 2 quarters · filed 2024-10-29 | $1.20M derived: sum of 3 quarters · filed 2024-10-29 | $1.82M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-28 | $987.00K derived: sum of 2 quarters · filed 2024-08-28 | $1.60M derived: sum of 3 quarters · filed 2024-08-28 | $1.75M 10-K · filed 2024-08-28 |
| 2023-03-31 | $496.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-02 | $1.11M derived: sum of 2 quarters · filed 2024-05-02 | $1.26M 10-Q · filed 2024-05-02 | $1.81M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $618.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-01-30 | $761.00K 10-Q · filed 2024-01-30 | $1.32M derived: sum of 3 quarters · filed 2024-01-30 | $1.47M derived: sum of 4 quarters · filed 2024-01-30 |
| 2022-09-30 | $143.00K 10-Q · filed 2023-11-09 | $701.00K derived: sum of 2 quarters · filed 2023-11-09 | $850.00K derived: sum of 3 quarters · filed 2023-11-09 | $1.37M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-28 | $707.00K derived: sum of 2 quarters · filed 2023-08-28 | $1.23M derived: sum of 3 quarters · filed 2023-08-28 | $1.79M 10-K · filed 2023-08-28 |
| 2022-03-31 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-04 | $670.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.23M 10-Q · filed 2023-05-04 | $1.38M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $521.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-02 | $1.08M 10-Q · filed 2023-02-02 | $1.23M derived: sum of 3 quarters · filed 2023-02-02 | |
| 2021-09-30 | $558.00K 10-Q · filed 2022-11-02 | $707.00K derived: sum of 2 quarters · filed 2022-11-02 | ||
| 2021-06-30 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-23 | $2.37M 10-K · filed 2022-08-23 | ||
| 2021-03-31 | $2.22M 10-Q · filed 2022-05-03 | |||
| 2020-06-30 | $2.32M 10-K · filed 2022-08-23 | |||
| 2019-06-30 | $0.00 10-K · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |